Rhone-Poulenc Taxotere, Campto Propel Oncology Sales To 39% Growth
Executive Summary
Sales of Rhone-Poulenc's Taxotere (docetaxel) jumped 40.9% (excluding the impact of exchange rates) to $116 mil. in the second quarter, leading the firm's oncology revenues.
You may also be interested in...
Lovenox Cost-Effectiveness Over Heparin Highlighted In ACC/AHA Guidelines
The cost-effectiveness of Rhone-Poulenc Rorer's Lovenox relative to unfractionated heparin in the treatment of unstable angina/non-Q-wave myocardial infarction is discussed in the 1999 American College of Cardiology/ American Heart Association practice guidelines.
Lovenox Cost-Effectiveness Over Heparin Highlighted In ACC/AHA Guidelines
The cost-effectiveness of Rhone-Poulenc Rorer's Lovenox relative to unfractionated heparin in the treatment of unstable angina/non-Q-wave myocardial infarction is discussed in the 1999 American College of Cardiology/ American Heart Association practice guidelines.
P&U Predicts Fourth Quarter Launch For "Approvable" Antidepressant Vestra
Pharmacia & Upjohn and co-promotion partner Janssen expect a fourth quarter launch for the antidepressant Vestra (reboxetine), following FDA "approvable" designation July 29.